Loading
A phase 1/2 trial of Photodynamic Therapy (PDT) in prostate cancer, run by SpectraCure AB, now recruiting.
Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System is a phase 1/2 interventional study registered as NCT06807359 by SpectraCure AB, with 43 participants planned, started 2025-01-06 and due to reach its primary completion in 2028-01. Interventions recorded: Photodynamic Therapy (PDT) and Verteporfin Injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares SpectraCure, Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/